Sagida Bibi Selected Research

ChAdOx1 nCoV-19

11/2022	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
7/2022	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
12/2021	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
11/2021	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
10/2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
10/2021	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
7/2021	T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire.
1/2021	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
1/2021	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
1/2020	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sagida Bibi Research Topics

Disease

16	COVID-19 11/2022 - 01/2020
10	Infections 01/2022 - 01/2020
3	Pain (Aches) 11/2022 - 01/2020
3	Fever (Fevers) 11/2022 - 01/2021
2	Whooping Cough (Pertussis) 01/2022 - 01/2021
2	Headache (Headaches) 12/2021 - 01/2020
2	Cough 10/2021 - 01/2021
2	Ageusia (Hypogeusia) 10/2021 - 01/2021
2	Anosmia 10/2021 - 01/2021
2	Dyspnea (Shortness of Breath) 10/2021 - 01/2021
1	Typhoid Fever (Typhoid) 01/2022
1	Breakthrough Infections 01/2022
1	Reactive Arthritis (Reiter Disease) 01/2022
1	Asymptomatic Infections 11/2021
1	Chills 01/2020

Drug/Important Bio-Agent (IBA)

15	VaccinesIBA 07/2022 - 01/2021
10	ChAdOx1 nCoV-19IBA 11/2022 - 01/2020
4	Nucleic AcidsIBA 07/2022 - 01/2021
4	AntibodiesIBA 01/2022 - 01/2021
2	AntigensIBA 01/2022 - 01/2021
2	MenACWYIBA 10/2021 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2020
1	Meningococcal Vaccines (Meningococcal Vaccine)IBA 11/2022
1	Antiviral Agents (Antivirals)IBA 10/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	sinovac COVID-19 vaccineIBA 01/2022
1	HLA-B Antigens (HLA-B)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 11/2021
1	P-2 (P 2)IBA 10/2021
1	Neutralizing AntibodiesIBA 01/2021
1	Pertussis ToxinIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2020
1	Immunoglobulin M (IgM)IBA 01/2020
1	Viral RNAIBA 01/2020

Therapy/Procedure

1	Therapeutics 01/2022
1	Intramuscular Injections 01/2020